# Tolerance, Pharmacokinetics / Pharmacodynamics (PK / PD) and Immunogenicity of Pegylated Uric Acid Oxidase for Injection in Healthy Adults and Hyperuricemia Volunteers

> **NCT05226013** · PHASE1 · UNKNOWN · sponsor: **The Affiliated Hospital of Qingdao University** · enrollment: 54 (estimated)

## Conditions studied

- Hyperuricemia

## Interventions

- **DRUG:** Polyglycol lated urate oxidase for injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05226013
- **Lead sponsor:** The Affiliated Hospital of Qingdao University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-08
- **Primary completion:** 2022-12-01
- **Final completion:** 2023-04-01
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2022-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05226013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05226013, "Tolerance, Pharmacokinetics / Pharmacodynamics (PK / PD) and Immunogenicity of Pegylated Uric Acid Oxidase for Injection in Healthy Adults and Hyperuricemia Volunteers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05226013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*